Serotonin Receptor Antagonists and Chemotherapy Administered to Patients: Interventions to Decrease Adverse Cardiac Events

Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review

Tricco AC, Soobiah C, Hui W, Antony J, Struchkov V, Hutton B, Hemmelgarn B, Moher D, Straus SE. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review. BMC Pharmacol Toxicol. 2015 Jan 26;16:1. doi: 10.1186/2050-6511-16-1.

Impact for Knowledge Users
Bottom Line
Protocol
Findings

Provided Health Canada with evidence on the safety of these agents for their decision-making

ECG monitoring of chemotherapy patients administered with serotonin (5-HT3) receptor antagonists did not reveal clinically significant differences in arrhythmia between the medications at the examined time periods